Zobrazeno 1 - 10
of 307
pro vyhledávání: '"Margarita Majem"'
Autor:
Ana Pardessus Otero, Albert Rafecas-Codern, José M. Porcel, Pere Serra-Mitjà, Lucía Ferreiro, Maribel Botana-Rial, Cristina Ramos-Hernández, José Manuel Brenes, Lydia Canales, Valle Camacho, Beatriz Romero-Romero, Juan Carlos Trujillo, Elisabeth Martinez, Enrique Cases, Andrés Barba, Margarita Majem, Ernest Güell, Virginia Pajares
Publikováno v:
Open Respiratory Archives, Vol 6, Iss 4, Pp 100349- (2024)
Malignant pleural effusion (MPE) has become an increasingly prevalent complication in oncological patients, negatively impacting their quality of life and casting a shadow over their prognosis. Owing to the pathophysiological mechanisms involved and
Externí odkaz:
https://doaj.org/article/c1d5ecfd9b5f4dce8fc10623eb9f4223
Autor:
Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100725- (2024)
Introduction: Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4+ and CD8+) activation and helps overcome resistance to programmed cell death protein 1 or programmed cell death-l
Externí odkaz:
https://doaj.org/article/12c20e7bd714464f84bdef20677b2f93
Autor:
Andrés Barba, Laura López-Vilaró, Malena Ferre, Margarita Majem, Sergio Martinez-Recio, Olga Bell, María J. Arranz, Juliana Salazar, Ivana Sullivan
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1121 (2024)
Standard first-line chemotherapy in small cell lung cancer (SCLC) is based on the platinum plus etoposide combination. Despite a high objective response rate, responses are not durable and chemotherapy-induced toxicity may compromise treatment. Genet
Externí odkaz:
https://doaj.org/article/531645fcd5b949e6bab2494a8cfc6895
Autor:
Esther Conde, MD, PhD, Susana Hernandez, PhD, Jose Luis Rodriguez Carrillo, MD, Rebeca Martinez, APT, Marta Alonso, APT, Daniel Curto, MD, Beatriz Jimenez, MD, Alejandra Caminoa, MD, PhD, Amparo Benito, MD, Pilar Garrido, MD, PhD, Sergi Clave, PhD, Edurne Arriola, MD, PhD, Isabel Esteban-Rodriguez, MD, PhD, Javier De Castro, MD, PhD, Irene Sansano, MD, Enriqueta Felip, MD, PhD, Federico Rojo, MD, PhD, Manuel Dómine, MD, PhD, Ihab Abdulkader, MD, PhD, Jorge Garcia-Gonzalez, MD, Cristina Teixido, PhD, Noemi Reguart, MD, PhD, Desamparados Compañ, MD, PhD, Amelia Insa, MD, Nuria Mancheño, MD, PhD, Sarai Palanca, MD, PhD, Oscar Juan-Vidal, MD, PhD, Nuria Baixeras, MD, Ernest Nadal, MD, PhD, Maria Cebollero, MD, Antonio Calles, MD, Paloma Martin, MD, PhD, Clara Salas, MD, PhD, Mariano Provencio, MD, PhD, Ignacio Aranda, MD, PhD, Bartomeu Massuti, MD, Laura Lopez-Vilaro, MD, Margarita Majem, MD, PhD, Luis Paz-Ares, MD, PhD, Fernando Lopez-Rios, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100653- (2024)
Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencin
Externí odkaz:
https://doaj.org/article/a3e58ca9d39948fda3972ff1d75a8f34
Autor:
Leticia Alserawan, Maria Mulet, Geòrgia Anguera, Mariona Riudavets, Carlos Zamora, Rubén Osuna-Gómez, Jorgina Serra-López, Andrés Barba Joaquín, Ivana Sullivan, Margarita Majem, Silvia Vidal
Publikováno v:
Cancers, Vol 16, Iss 9, p 1759 (2024)
Immune checkpoint inhibitors (ICI) have the potential to trigger unpredictable immune-related adverse events (irAEs), which can be severe. The underlying mechanisms of these events are not fully understood. As PD-L1 is upregulated by IFN, the heighte
Externí odkaz:
https://doaj.org/article/0f1cc93e70d84d2c859da4b14f14a5af
Autor:
Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/6b475fde214d41829d313ffd4989b729
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimer
Externí odkaz:
https://doaj.org/article/44b83896764b4d85bc01ecb3c4630dd4
Autor:
Georgia Anguera, Maria Mulet, Carlos Zamora, Rubén Osuna-Gómez, Andrés Barba, Ivana Sullivan, Jorgina Serra-López, Elisabet Cantó, Silvia Vidal, Margarita Majem
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 958 (2024)
PD-(L)1 inhibitors are part of the treatment strategy for non-small cell lung cancer (NSCLC) although its efficacy is limited to certain patients. Our study aimed to identify patients who might benefit from anti-PD-(L)1 inhibitors by analyzing the PD
Externí odkaz:
https://doaj.org/article/1743b63c341c4a9a946584a3e7e487fc
Autor:
Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/9ac77df433144c60bb72e35db443b3df
Autor:
Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez, Rocío López-Vacas, Virtudes Soriano, Fernando Garicano, M. José Lecumberri, María Rodríguez de la Borbolla, Margarita Majem, Elisabeth Pérez-Ruiz, María González-Cao, Juana Oramas, Alejandra Magdaleno, Joaquín Fra, Alfonso Martín-Carnicero, Mónica Corral, Teresa Puértolas, Ricardo Ramos-Ruiz, Antje Dittmann, Paolo Nanni, Juan Ángel Fresno Vara, Enrique Espinosa
Publikováno v:
Cancers, Vol 15, Iss 17, p 4407 (2023)
Immunotherapy improves the survival of patients with advanced melanoma, 40% of whom become long-term responders. However, not all patients respond to immunotherapy. Further knowledge of the processes involved in the response and resistance to immunot
Externí odkaz:
https://doaj.org/article/6da6bdb748d84ad08bfecc4b64fa7420